Literature DB >> 18475414

Comparative study of the effectiveness of oral fluconazole and intravaginal clotrimazole in the treatment of vaginal candidiasis.

H Mikamo1, K Izumi, K Ito, T Tamaya.   

Abstract

OBJECTIVE: A study was carried out to compare 3 treatment regimens for vaginal candidiasis.
METHODS: A total of 150 women with clinical and mycological evidence of vaginal candidiasis were randomized to receive 50 mg of oral fluconazole daily for 6 days (50 women), a single oral 150 mg dose of fluconazole (50 women), or 100 mg of intravaginal clotrimazole daily for 6 days (50 women). They were assessed at 5-15 days (short-term assessment) and again at 30-60 days (long-term assessment) after the completion of treatment.
RESULTS: Candida species were completely eradicated from the vagina in 88% or 80% in the 6-day oral fluconzaole group, 76% or 70% in the single oral fluconazole group, and 72% or 60% in the intravaginal clotrimazole group at short-term or long-term assessment, respectively. The rates of clinical effectiveness were 92% or 88% in the 6-day oral fluconzaole group, 80% or 76% in the single oral fluconazole group, and 72% or 58% in the intravaginal clotrimazole group at the short-term or long-term assessment, respectively. Treatment-related side effects were not found in any group.
CONCLUSIONS: This study suggests that the treatment of vaginal candidiasis with oral fluconazole is effective and that a single oral fluconazole dose might be one choice in the treatment of vaginal candidiasis.

Entities:  

Year:  1995        PMID: 18475414      PMCID: PMC2364408          DOI: 10.1155/S1064744995000238

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  12 in total

1.  An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice.

Authors:  R J Phillips; S A Watson; F F McKay
Journal:  Br J Clin Pract       Date:  1990-06

2.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.

Authors:  M P Bisschop; J M Merkus; H Scheygrond; J Van Cutsem; A van de Kuy
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1979-08       Impact factor: 2.435

4.  Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans.

Authors:  M I O'Connor; J D Sobel
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

5.  A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial.

Authors:  E Kutzer; R Oittner; S Leodolter; K W Brammer
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1988-12       Impact factor: 2.435

6.  Genital candidosis.

Authors:  F C Odds
Journal:  Clin Exp Dermatol       Date:  1982-07       Impact factor: 3.470

7.  Recurrent vaginal candidiasis. Importance of an intestinal reservoir.

Authors:  M R Miles; L Olsen; A Rogers
Journal:  JAMA       Date:  1977-10-24       Impact factor: 56.272

8.  Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis.

Authors:  G E Stein; S Christensen; N Mummaw
Journal:  DICP       Date:  1991-06

Review 9.  Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use.

Authors:  J H Van Tyle
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

10.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  3 in total

1.  Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis.

Authors:  Fen Qin; Quan Wang; Chunlian Zhang; Caiyun Fang; Liping Zhang; Hailin Chen; Mi Zhang; Fei Cheng
Journal:  Infect Drug Resist       Date:  2018-10-17       Impact factor: 4.003

2.  Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten®.

Authors:  Lei Zhang; Raffaella De Salvo; Andreas Ehret; Kimberley Young; Sonja Trapp
Journal:  SAGE Open Med       Date:  2022-03-28

3.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).

Authors:  Hayley J Denison; Julia Worswick; Christine M Bond; Jeremy M Grimshaw; Alain Mayhew; Shakila Gnani Ramadoss; Clare Robertson; Mary Ellen Schaafsma; Margaret C Watson
Journal:  Cochrane Database Syst Rev       Date:  2020-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.